

## HR 1873

### Advancing Education on Biosimilars Act of 2021

**Congress:** 117 (2021–2023, Ended)

**Chamber:** House

**Policy Area:** Health

**Introduced:** Mar 12, 2021

**Current Status:** Referred to the Subcommittee on Health.

**Latest Action:** Referred to the Subcommittee on Health. (Mar 16, 2021)

**Official Text:** <https://www.congress.gov/bill/117th-congress/house-bill/1873>

## Sponsor

**Name:** Rep. Bucshon, Larry [R-IN-8]

**Party:** Republican • **State:** IN • **Chamber:** House

## Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Peters, Scott H. [D-CA-52]	D · CA		Mar 12, 2021

## Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Mar 16, 2021

## Subjects & Policy Tags

### Policy Area:

Health

## Related Bills

Bill	Relationship	Last Action
117 HR 19	Related bill	Oct 19, 2021: Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
117 S 164	Identical bill	Apr 23, 2021: Became Public Law No: 117-8.

## Summary (as of Mar 12, 2021)

### Advancing Education on Biosimilars Act of 2021

This bill requires the Food and Drug Administration (FDA) to advance education and awareness among health care providers about biological products as appropriate, including by developing or improving continuing education programs that address the prescribing of biological products and biosimilars. (A biosimilar is a biological product that is highly similar to an FDA-approved reference biological product and has no clinically meaningful differences from that reference product.)

The FDA may also maintain and operate a website to provide educational materials about biological products.

## **Actions Timeline**

---

- **Mar 16, 2021:** Referred to the Subcommittee on Health.
- **Mar 12, 2021:** Introduced in House
- **Mar 12, 2021:** Referred to the House Committee on Energy and Commerce.